Defibrotide's diverse therapeutic effects are proposed to stem from a unified mechanism of antiendothelial cell activation.
May unify defibrotide's pleiotropic effects under endothelial protection; hypothesis-generating and requires prospective validation.
Defibrotide has several activities [profibrinolytic, antithrombotic‐thrombolytic, anti‐ischemic (heart, liver, kidney, skin, brain), antishock, antiatherosclerotic, and antirejection]. This host of activities has puzzled several people accustomed to the concept: one drug — one activity. But, if you see defibrotide as an antiendothelial cell activation drug, each piece of the puzzle will neatly fit into its right place and the host of activities becomes an array of activities. In fact the polyhedric inflammatory process is the common background of seemingly different illnesses, both acute and chronic. So the old concept of one drug‐one activity proves true; one drug: defibrotide — one activity; antiendothelial cell activation activity.
No takes yet. Share an insight, caveat, or question.
Pescador et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: